Latest News for: bristol-myers

Edit

Chemotherapy Induced Anemia Drugs Market 2032: Clinical Trials, Medication, Prevalence, Statistics, Revenue, Therapies, EMA, PDMA, ...

GetNews 28 Mar 2025
Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen Inc., Novartis AG, 3SBio Group, Bristol-Myers Squibb, FibroGen, and others ... Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen Inc., Novartis AG, 3SBio Group, Bristol-Myers Squibb, FibroGen, and others.
Edit

Peripheral T-cell Lymphoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, ...

GetNews 28 Mar 2025
"Peripheral T-cell Lymphoma Market" ... The report is divided into segments covering seven major markets ... Request for a Free Sample Report @. Some facts of the Peripheral T-cell Lymphoma Market Report are ... (NASDAQ ... Bristol-Myers Squibb Bavencio (avelumab) ... 1.
Edit

Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks

The Call 27 Mar 2025
Bristol-Myers Squibb (NYSE ... With roots dating back to 1887 and a transformative merger in 1989 that gave the company its current name, Bristol-Myers Squibb (NYSE ... Bristol-Myers Squibb reported revenues of $12.34 billion, up 7.5% year on year.
Edit

Additional Proxy Soliciting Materials (Form DEFA14A) (Bristol-Myers Squibb Company)

Public Technologies 26 Mar 2025
Bristol-Myers Squibb Company ... Your Vote Counts! BRISTOL-MYERS SQUIBB COMPANY2025 Annual Meeting Voteby May 5, 2025 11.59 PM ET ... Bristol-Myers Squibb Company published this content on March 26, 2025, and ...
Edit

Colorectal Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 26 Mar 2025
In March 2025, Bristol-Myers Squibb organized a study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
Edit

Global 3D Cell Culture Market Size, Trends, Industry Analysis | Double-Digit Growth by 2027

Pharmiweb 26 Mar 2025
For instance, In June 2023, Bristol Myers Squibb received approval from the U.S ... This facility is a vital part of Bristol Myers Squibb's growing global network for producing cell therapies, ...
Edit

Proxy Statement (Form DEF 14A) (Bristol-Myers Squibb Company)

Public Technologies 26 Mar 2025
Bristol-Myers Squibb Company ... Bristol Myers Squibb ... 2024 was a productive year driven by strong execution for Bristol Myers Squibb (BMS) ... Thank you for your continued investment in Bristol Myers Squibb and for your support of our mission.
Edit

SCHD ETF: brace for big changes on this blue-chip fund next week

Invezz 25 Mar 2025
The SCHD ETF has done well for two main reasons ... Technology companies account for just 10% of the fund ... The biggest names in the fund are in the pharmaceutical sector, and are firms like AbbVie, Amgen, Bristol-Myers Squibb, and Pfizer ... ....
Edit

Diffuse Large B-cell Lymphoma Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Insights Unveiled ...

GetNews 25 Mar 2025
(NYSE ... Key companies developing therapies for Diffuse Large B-cell Lymphoma are - AstraZeneca, Bristol-Myers Squibb, Seattle Genetics/Takeda, ADC Therapeutics, SymBio Pharmaceuticals, Denovo Biopharma, Merck, Amgen, TG Therapeutics, Bayer and others.
Edit

Non-Hodgkin’s Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 25 Mar 2025
In March 2025, Bristol-Myers Squibb organized a phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult ...
×